Vol. I · No. 33
Thursday, August 13, 2026
Issue: Summer · 2026
Established · MMXXVI
— The evidence base for longevity medicine —
Indexed by PubMed · CTG · Cochrane
Editorial team · geroevidence.com
Subscription · app.geroevidence.com

DHEA and aging: what the human trial evidence shows

DHEA is the most abundant circulating steroid hormone and declines by 80–90% between age 25 and 80. It is one of the most prescribed hormones in longevity medicine — and its hard-outcome evidence is considerably weaker than the prescribing pattern suggests.

By Geroevidence editorial team·Published 19 July 2026·Category Intervention Profiles·11 min read
Emerging
Evidence tier
Surrogate endpoints only
80–90%
Decline age 25→80
Most dramatic hormone decline
25–50mg
Typical supplementation dose
Oral daily
None
Mortality trial data
No hard longevity outcomes
§ DHEA SERUM LEVELS BY DECADE · AVERAGE DECLINE CURVE Peak 10% Age 25 · peak Age 80 · −85% 20s 30s–40s 50s–60s 70s–80s Observational association with longevity does not establish causation
Fig. 1 — DHEA-S (the sulfated storage form) declines more steeply with age than almost any other hormone. The age-associated decline is well-documented; whether restoring levels to youthful concentrations produces longevity benefit is not established by current evidence.
§ Why DHEA attracts longevity interest

DHEA-S levels are among the strongest hormonal predictors of all-cause mortality in epidemiological studies — lower levels are consistently associated with higher mortality across multiple cohorts. This correlation is one of the most robust in aging biology.

DHEA serves as a precursor for both testosterone and estrogen. It has direct effects on immune function, bone density, and metabolic parameters independent of its role as a sex hormone precursor. The hypothesis that restoring declining DHEA levels could slow or reverse age-related decline is mechanistically coherent.

The critical distinction — consistently underemphasized in longevity medicine discussions — is between the observational association of low DHEA with mortality and the question of whether supplementing DHEA in older adults reduces mortality. These are fundamentally different questions, and the evidence base answers them differently.

§ The human trial evidence
RCT
DHEA and Well-Being Study (DAWN) — Baulieu et al., PNAS, 2000
n=280
Adults 60–79. DHEA 50mg daily for 1 year. Improved bone density in women over 70, improved libido in women, modest skin improvement. No significant effect on muscle strength, memory, quality of life, or overall wellbeing in the primary analysis. One of the most rigorously conducted DHEA trials.
RCT
DHEA supplementation and cognitive function — Wolf et al., 1998
n=40
Older adults. DHEA 50mg daily for 2 weeks showed improvement in working memory in one session but not in replication. Short duration, small sample, inconsistent within-study results.
RCT
Nair et al. — NEJM, 2006
n=87
Men and women 60–88 with low serum DHEA-S. 2 years of DHEA supplementation. No significant effect on body composition, physical performance, insulin sensitivity, or quality of life. Well-conducted, adequate power, appropriate duration. Largely negative result in the outcome domains most clinically relevant to longevity.
§ The honest clinical position

DHEA is one of the most widely prescribed interventions in longevity medicine, and its evidence base for hard longevity outcomes is one of the weakest among commonly prescribed longevity interventions. The epidemiological association is compelling; the intervention trials are largely neutral or show effects only on surrogate endpoints.

The evidence tier is Emerging — based on the bone density signal in older women and the epidemiological association, with the understanding that this is a weak evidence base for a widely used intervention. A physician prescribing DHEA for longevity should communicate that the observational evidence does not establish that supplementation reduces mortality, and that the most rigorous intervention trials have been largely neutral.

This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.

Full intervention profiles
Daily alerts · trial updates · evidence changes
Start free trial
14 DAYS FREE · NO CARD REQUIRED
At a glance
Drug class
Endogenous steroid hormone
Pathway
Sex hormone precursor · immune
Evidence tier
Emerging
Key RCT
Nair 2006 NEJM · largely neutral
Typical dose
25–50mg daily oral
Hard outcome data
None
Related interventions
Rapamycin
mTOR inhibitor
Moderate
Metformin
AMPK activator
Moderate
NMN
NAD+ precursor
Emerging
View full index →